Recommended regimens listed by evidence level and alphabetically for:Peginterferon/Ribavirin-Experienced, Genotype 1a Patients Without Cirrhosis |
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsa for elbasvir | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 8 weeks | I, A |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
a Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance to elbasvir. Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 1a Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients without baseline NS5A RASsb for elbasvir | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c | 12 weeks | I, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin | 12 weeks | I, A |
a For decompensated cirrhosis, please refer to the appropriate section. b Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance to elbasvir. Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens. c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 1b Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 12 weeks | I, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin | 12 weeks | I, A |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended and alternative regimens listed by evidence level and alphabetically for:NS3 Protease Inhibitor (Telaprevir, Boceprevir, or Simeprevir) + Peginterferon/Ribavirin-Experienced, Genotype 1 Patients Without Cirrhosis |
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | I, A |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)a | 12 weeks | IIa, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for all genotype 1b patients, and genotype 1a patients without baseline NS5A RASsb for elbasvir | 12 weeks | IIa, B |
|
||
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for genotype 1a patients with baseline NS5A RASsb for elbasvir | 16 weeks | IIa, B |
a Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. b Includes genotype 1a RASs at amino acid positions 28, 30, 31, or 93 known to confer antiviral resistance to elbasvir. Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
NS3 Protease Inhibitor (Telaprevir, Boceprevir, or Simeprevir) + Peginterferon/Ribavirin Treatment-Experienced, Genotype 1 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 12 weeks | IIa, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin | 12 weeks | I, A |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for all genotype 1b patients, and genotype 1a patients without baseline NS5A RASsc for elbasvir | 12 weeks | IIa, B |
|
||
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) plus weight-based ribavirin for genotype 1a patients with baseline NS5A RASsc for elbasvir | 16 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. c Includes genotype 1a RASs at amino acid position 28, 30, 31, or 93 known to confer antiviral resistance to elbasvir. Baseline testing for these RASs is recommended for patients receiving elbasvir/grazoprevir-based regimens. |
Recommended regimens listed by evidence level and alphabetically for:
Non-NS5A Inhibitor, Sofosbuvir-Containing Regimen-Experienced, Genotype 1 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for genotype 1a patients | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b, regardless of subtype | 12 weeks | IIa, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) for genotype 1b patients | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
NS5A Inhibitor DAA-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 1 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | I, A |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b except NS3/4 protease inhibitor inclusive DAA combination regimens | 16 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 2 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 12 weeks | I, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimens listed by evidence level for:
Sofosbuvir + Ribavirin-Experienced, Genotype 2 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, B |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 12 weeks | IIb, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimen for:
Sofosbuvir + NS5A Inhibitor-Experienced (Excluding Glecaprevir/Pibrentasvir Failures), Genotype 2 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | I, B |
a For decompensated cirrhosis, please refer to the appropriate section. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 3 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 16 weeks | IIa, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | IIb, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily fixed-dose elbasvir (50 mg)/grazoprevir (100 mg) plus sofosbuvir (400 mg) | 12 weeks | I, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) plus weight-based ribavirin | 12 weeks | II, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimens by evidence level for:
Sofosbuvir + Ribavirin-Experienced (± Peginterferon), Genotype 3 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100mg) | 12 weeks | I, B |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b | 16 weeks | IIb, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimen for:
DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 3 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | I, A |
|
||
For patients with prior NS5A inhibitor failure and cirrhosis, addition of weight-based ribavirin is recommended. | 12 weeks | IIa, C |
a For decompensated cirrhosis, please refer to the appropriate section. |
Recommended and alternative regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 4 Patients With Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | I, A |
Daily fixed-dose combination of elbasvir (50 mg)/grazoprevir (100 mg) for patients who experienced virologic relapse after prior peginterferon/ribavirin therapyb | 12 weeks | IIa, B |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)c | 12 weeks | IIa, B |
ALTERNATIVE | DURATION |
RATING ![]() |
Daily ledipasvir (90 mg)/sofosbuvir (400 mg) plus weight-based ribavirin | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b If the type of prior treatment failure (relapse vs breakthrough/nonresponse) is unknown, another recommended regimen should be used. c Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimen for:
DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 4 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | I, A |
a For decompensated cirrhosis, please refer to the appropriate section. |
Recommended regimens listed by evidence level and alphabetically for:
Peginterferon/Ribavirin-Experienced, Genotype 5 or 6 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b for patients without cirrhosis | 8 weeks | IIa, B |
|
||
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b for patients with compensated cirrhosis | 12 weeks | I, B |
Daily fixed-dose combination ledipasvir (90 mg)/sofosbuvir (400 mg) | 12 weeks | IIa, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg) | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimen for:
DAA-Experienced (Including NS5A Inhibitors Except Glecaprevir/Pibrentasvir Failures), Genotype 5 or 6 Patients, With or Without Compensated Cirrhosisa
|
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | IIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. |
Recommended regimens listed by evidence level and alphabetically for:Patients With Prior Glecaprevir/Pibrentasvir Treatment Failure (All Genotypes), With or Without Compensated Cirrhosisa |
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b plus daily sofosbuvir (400 mg) and weight-based ribavirin | 16 weeks | IIa, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) | 12 weeks | IIa, B |
|
||
For patients with compensated cirrhosis, addition of weight-based ribavirin is recommended. | 12 weeks | IIa, C |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |
Recommended regimens listed by evidence level and alphabetically for:Patients With Prior Sofosbuvir/Velpatasvir/Voxilaprevir Treatment Failure (All Genotypes), With or Without Compensated Cirrhosisa |
||
---|---|---|
RECOMMENDED | DURATION |
RATING ![]() |
Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg)b plus daily sofosbuvir (400 mg) and weight-based ribavirin | 16 weeks | IIIa, B |
Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) plus weight-based ribavirin | 24 weeks | IIIa, B |
a For decompensated cirrhosis, please refer to the appropriate section. b Dosing is 3 coformulated tablets (glecaprevir [100 mg]/pibrentasvir [40 mg]) taken once daily. Please refer to the prescribing information. |